| 1 |
34697142 | Contribution of Glucosylceramide Synthase to the Proliferation of Mouse Osteoblasts. | 2021 Nov-Dec |
1 |
| 2 |
28610891 | N-butyldeoxynojirimycin delays motor deficits, cerebellar microgliosis, and Purkinje cell loss in a mouse model of mucolipidosis type IV. | 2017 Sep |
4 |
| 3 |
26771826 | Gpnmb Is a Potential Marker for the Visceral Pathology in Niemann-Pick Type C Disease. | 2016 |
2 |
| 4 |
27106513 | N-butyldeoxynojirimycin treatment restores the innate fear response and improves learning in mucopolysaccharidosis IIIA mice. | 2016 Jun |
1 |
| 5 |
25915583 | Glycosphingolipid synthesis inhibition limits osteoclast activation and myeloma bone disease. | 2015 Jun |
2 |
| 6 |
21738789 | Iminosugar-based inhibitors of glucosylceramide synthase increase brain glycosphingolipids and survival in a mouse model of Sandhoff disease. | 2011 |
1 |
| 7 |
18387328 | Beneficial effects of substrate reduction therapy in a mouse model of GM1 gangliosidosis. | 2008 Jun |
1 |
| 8 |
12692077 | The absence of functional glucosylceramide synthase does not sensitize melanoma cells for anticancer drugs. | 2003 Jun |
1 |
| 9 |
11525744 | Critical role for glycosphingolipids in Niemann-Pick disease type C. | 2001 Aug 21 |
2 |
| 10 |
10841515 | Reduction of globotriaosylceramide in Fabry disease mice by substrate deprivation. | 2000 Jun |
1 |